Showing results (581-590 of 1,547) with videos related to
Sort By:
Pageof 155
Journal of Neuroinflammation|June 29, 2016
New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studiesT Sehr, U Proschmann, K Thomas, et al.Environmental Science & Technology|December 6, 2012
Methodologies for assessing the use-phase power consumption and greenhouse gas emissions of telecommunications network servicesChien A Chan, André F Gygax, Elaine Wong, et al.Oral Oncology|June 19, 2012
Epithelial to mesenchymal transition (EMT) biomarkers--E-cadherin, beta-catenin, APC and Vimentin--in oral squamous cell carcinogenesis and transformationS Y Chaw, A Abdul Majeed, A J Dalley, et al.Multiple Sclerosis and Related Disorders|July 10, 2022
Ocrelizumab-related neutropenia: Effects of age, sex and bodyweight using the FDA Adverse Event Reporting System (FAERS)H Hammer, N Kamber, M Pistor, et al.Archives of Neurology|December 29, 1998
Anticoagulation therapy in pediatric patients with sinovenous thrombosis: a cohort studyG deVeber, A Chan, P Monagle, et al.BMC Infectious Diseases|April 4, 2025
After the program ends: HIV testing behavior among men who have sex when men after the conclusion of a program providing regular home delivery of HIV self-testing kitsTyler B Wray, Philip A Chan, Jeffrey D Klausner, et al.Endocrinology|December 11, 2012
PACAP controls adrenomedullary catecholamine secretion and expression of catecholamine biosynthetic enzymes at high splanchnic nerve firing rates characteristic of stress transduction in male miceN Stroth, B A Kuri, T Mustafa, et al.Journal of Pediatric Endocrinology & Metabolism : JPEM|July 7, 1999
Diabetes complication screening in 937 children and adolescentsK C Donaghue, J M Fairchild, A Chan, et al.Acta Neurochirurgica|July 10, 1999
Fosphenytoin reduces hippocampal neuronal damage in rat following transient global ischemiaS A Chan, K H Reid, A Schurr, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 6, 2018
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinicT A Chan, M Yarchoan, E Jaffee, et al.Pageof 155